XOMA Royalty

The balanced approach the team is taking to build the scale of XOMA Royalty’s portfolio is beginning to bear fruit.?Owen Hughes highlighted 2024’s performance and what we’re focused on in 2025.?“Our growing royalty portfolio has 6 commercial assets, including the recently launched OJEMDA? (Day One) and MIPLYFFA? (Zevra).?There are now 11 assets in Phase 3 development, two of which have expected readouts in 2025, ersodetug from Rezolute and seralutinib from Gossamer Bio.?With over $100 million in cash on hand and a clear path to sustainable cashflow from royalties alone, we are well-positioned to further our goal of driving value for patients and shareholders alike.”?You can read the full release here?https://bit.ly/427PjBL XOMA Royalty #Royalty #Royalties #Milestones #monetization #partner #partnering #alternativefinance #capital #acquistion Day One Biopharmaceuticals #OJEMDA Zevra Therapeutics #MIPLYFFA Day One Biopharmaceuticals Rezolute, Inc. #ersodetug Gossamer Bio #seralutinib

We invite you to listen to the replay of Owen Hughes and Brad Sitko’s in-depth conversation with David Risinger at Leerink Partners’ recent Global Healthcare Conference.?The replay can be accessed here https://bit.ly/3DuCAzN XOMA Royalty #Royalty #Royalties #Milestones #monetization #partner #partnering #alternativefinance #capital #acquistion Leerink Partners #LeerinkHealthcareConference

Owen Hughes and Brad Sitko sat down with Matthew Pillar for an extended conversation during JPMorgan’s Healthcare Conference.?The discussion focused on royalty monetization as a funding mechanism for biotech companies and XOMA Royalty’s unique position in the royalty space, as well as broader macroeconomic dynamics impacting the biotech industry.??You can listen to the Business of Biotech podcast on your favorite podcast provider or watch the conversation here https://lnkd.in/g3uQpkpJ ? XOMA Royalty #Royalty #Royalties #Milestones #monetization #partner #partnering #alternativefinance #capital #acquistion #biotech #financing

We invite you to join us as Owen Hughes and Brad Sitko have a conversation with Phil Nadeau on Monday, March 3 at 11:10 am during T.D. Cowen’s 45th Annual Health Care Conference.??The fireside chat can be accessed here https://bit.ly/4icV5XY ? XOMA Royalty #Royalty #Royalties #Milestones #monetization #partner #partnering #alternativefinance #capital #acquistion Cowen Inc. Phil Nadeau Ernie Rodriguez Dumont, MD, MBA

XOMA Royalty’s team has added another Phase 3 asset to the portfolio and completed its first syndicated royalty financing transaction by?acquiring?an economic interest in Castle Creek Biosciences’ D-Fi?(FCX-007).?D-Fi?is being studied in dystrophic epidermolysis bullosa (DEB), a rare progressive and debilitating skin disorder.?With this addition, we now have 11 assets in our milestone and royalty portfolio that are in or entering Phase 3 clinical development.?Details on the syndicated royalty financing can be found here https://bit.ly/4hTZC1L. ? XOMA Royalty Castle Creek Biosciences, Inc. Paragon Biosciences Valor Equity Partners Ligand Pharmaceuticals #DFi #Royalty?#Royalties?#Milestones?#monetization?#partner?#partnering?#alternativefinance?#capital?#acquistion #Phase3 #OrphanDrug #RareDisease #RarePediatricDesignation

Thanks to Oppenheimer’s Trevor Allred?for the informative conversation with Owen Hughes?and Brad Sitko?about the XOMA Royalty business model.?If you missed it, you can access the replay here https://bit.ly/4132fZf XOMA Royalty #Royalty?#Royalties?#Milestones?#monetization?#partner?#partnering?#alternativefinance?#capital?Oppenheimer & Co. Inc.?#OppenheimerHealthcareConference?Joel Sendek?Leland Gershell?Arif B. Sheikh?Michael Margolis

Please join Oppenheimer’s Trevor Allred’s conversation with XOMA Royalty’s Owen Hughes and Brad Sitko.?The fireside chat takes place on Tuesday, February 11 at 3:20 pm ET.?You can access both the live event and replay here https://bit.ly/4132fZf XOMA Royalty #Royalty #Royalties #Milestones #monetization #partner #partnering #alternativefinance #capital Oppenheimer & Co. Inc. #OppenheimerHealthcareConference Joel Sendek Leland Gershell Arif B. Sheikh Michael Margolis?

Happy New Year from The Business of Biotech! We kicked off 2025 at the J.P. Morgan Healthcare Conference, recording a stellar podcast series with leaders from XOMA Royalty, Landmark Bio, QurAlis, and more. Big thanks to Alston & Bird for hosting us—if you need top biotech legal expertise, they’ve got you covered. Stay tuned for our JPM series, and check out some recent highlights from Life Science Connect below!

The XOMA Royalty team is pleased to support the Demy-Colton and EBD Group teams and the #BiotechShowcase. Innovate.?Connect.?Invest.??We look forward to connecting with clinical-stage companies who are considering non-dilutive financing options to further their innovative therapies!? ? Sara Jane Demy Lila Taylor Sara Pinto Lisa Brailsford #biotech #royalty #royalties #milestone #milestones #monetization #partner #partners #partnering #drugdevelopment #therapies #innovation #alternativefinance #capital #JPM #JPMHealthcareConference

On January 7, Rezolute, Inc. announced the FDA has granted Breakthrough Therapy Designation to ersodetug (RZ358) for the treatment of hypoglycemia due to congenital hyperinsulinism (CHI) from the FDA.?The CHI community has limited options and wants effective therapies with limited side effects that allow these babies and children to experience a normal childhood.??We looking forward to Rezolute’s updates in 2025, particularly the topline results from the #sunRIZE Phase 3 study that they anticipate during the second half of the year.? ? #Royalty #Royalties #CHI #ersodetug #RZ358 #RareDisease #BreakthroughTherapy #Milestone #Milestones #XOMALegacy?